NCT02049307View on ClinicalTrials.gov

Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

October 16, 2014

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions
InflammationFibrosis
Interventions
DRUG

Losartan 100mg daily

DRUG

Matching placebo

Trial Locations (4)

20892

NIH Clinical Center, Bethesda

55407

Allina Health, Minneapolis

55417

Hennepin County Medical Center, Minneapolis

94110

UCSF, San Francisco

Sponsors
All Listed Sponsors
lead

Hennepin Healthcare Research Institute

OTHER